You probably know your cholesterol number. Total cholesterol, LDL, HDL, triglycerides — the standard lipid panel most doctors order. There is a fifth number, carried in the same blood draw at most labs, that almost nobody in India has ever been asked to check: lipoprotein(a), written Lp(a) and said “L-P-little-a.”
In March 2026, eleven major American heart and medical organisations, including the American College of Cardiology and the American Heart Association, jointly recommended that every adult get this test at least once. Here is why it matters more if you or your family are South Asian, what the numbers actually mean, and what you can and cannot do about a high result today.
What Lp(a) actually is
Lp(a) is an LDL-like particle with an extra protein wrapped around it. Unlike LDL cholesterol, which responds to diet, exercise, weight loss and statins, Lp(a) is almost entirely set by your genes. Whatever level you are born with is roughly the level you carry for life. That is also why the new guideline calls for testing only once: unlike a cholesterol panel you might repeat every few years to track lifestyle changes, a stable genetic marker rarely needs rechecking.
A high Lp(a) is an independent risk factor for heart attack and stroke — it raises risk on its own, separately from LDL, blood pressure or blood sugar.
The 2026 guideline
The updated lipid management guideline, published jointly in the American College of Cardiology’s JACC and the American Heart Association’s Circulation in March 2026, states plainly that Lp(a) “should be measured at least once in adulthood.” It defines a high result as 125 nmol/L or 50 mg/dL or above, which it links to roughly a 1.4-fold higher long-term risk of heart attack or stroke. At 250 nmol/L, that long-term risk is described as at least double.
The guideline also names specific ancestry groups it considers a risk enhancer in its own right: “higher-risk ancestry such as South Asian or Filipino ancestry or other ancestral groups with an enhanced risk for developing atherosclerosis.”
Why this matters more for South Asians specifically
A 2025 review in the Journal of the American Heart Association lays out the case. South Asians make up roughly a quarter of the world’s population, and about a quarter of South Asians have Lp(a) levels above 50 mg/dL — the same threshold the 2026 guideline flags as high. The same review states that South Asians experience heart attacks nearly ten years earlier, on average, than people of European descent.
That earlier onset is usually explained by a combination of things: higher rates of diabetes and abdominal obesity at a given body weight, and, this review argues, a higher baseline prevalence of elevated Lp(a) than in Western populations. None of this is about individual lifestyle failure. It is a population-level genetic pattern that most people, including many doctors, were never taught to specifically test for.
If your number comes back high
Here is the honest part. There is currently no approved drug that lowers Lp(a) itself. Several are in development. The furthest along, pelacarsen, was being tested in a large Phase 3 trial specifically designed to see whether lowering Lp(a) actually prevents heart attacks and strokes, not just moves the number. In an announcement dated September 4, 2026, Novartis reported that this trial did not meet its main goal: pelacarsen lowered Lp(a) levels as expected, but that did not translate into fewer cardiovascular events in this trial population. Two other drugs, olpasiran and lepodisiran, remain in earlier-stage or ongoing trials, with results not yet available.
That result is a genuinely useful piece of evidence, not a discouraging footnote: it means lowering Lp(a) with a drug has not yet been proven to reduce heart attacks, even though it clearly moves the lab number. So a high Lp(a) today is not something a medicine can fix. What it changes is how aggressively your doctor may want to manage everything that is treatable: LDL cholesterol, blood pressure, blood sugar, and smoking. A high Lp(a) is a reason to be stricter about those, not a reason to feel there is nothing to be done.
Who should actually ask for the test
The guideline’s own framing is simple: every adult, once. In practice, it is worth asking specifically if you have a family history of early heart attack or stroke (in a parent or sibling before roughly age 55 for men or 65 for women), if you have had a heart attack or stroke yourself despite a normal LDL, or if you are of South Asian or Filipino ancestry and have never been tested. The test itself is a standard blood draw, usually available alongside a routine lipid panel at any diagnostic lab in India, though it is not part of the default panel most doctors order without being asked.
This article is educational and informational. It is not a diagnosis or personalised medical advice. Talk to your doctor about whether an Lp(a) test is right for you, and about your own cardiovascular risk overall.
Further Reading on Medimadad
Lp(a) is one piece of a bigger cardiometabolic picture. Our recent piece on fatty liver in India covers another silent risk factor that is often found on the same round of tests, and our guide to understanding your blood pressure numbers walks through the other reading worth tracking alongside your lipid panel.
Sources
- American College of Cardiology / American Heart Association et al. 2026 lipid management guideline. Published jointly in JACC and Circulation, March 13, 2026. American Heart Association newsroom summary.
- Patel D, Koschinsky ML, Agarwala A, et al. Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals. Journal of the American Heart Association, 2025. DOI 10.1161/JAHA.124.040361.
- Novartis. Pelacarsen Phase III Lp(a)HORIZON trial results announcement, September 4, 2026 (SEC Form 6-K).
To get informed about health issues, visit medimadad.com.
